Gabby

“I can appreciate removing the revenue guidance in terms of visibility, but could you help us size if you view the first quarter as sort of run rate once I back out the consolidation of NANX, health IT, and just kind of any sort of framing on how you expect what a more realistic 2026 revenue target is.”

“Could you help us get a little bit more comfortable with the second quarter to third quarter EBITDA ramp and maybe expand on what initiatives are kicking in? Maybe the second quarter EBITDA was just slightly softer than we had modeled.”

“I just wanted to double click on the payer mix and if you can share any color on how it played out compared to your internal expectations, specifically Medicaid infecting positively for the first time in 2025 and if that's something you expect to persist.”

“I wanted to double-click on the supplemental plans. As you get ready to roll those out for the 2026 selling season, should we think about that having impact on the expense line in 2026?”

“Could you just speak a little bit more to the commercial cost trends you saw in the fourth quarter and overall for 2024, maybe more by product, inpatient, outpatient, and then just reiterate what's assumed in guidance for how commercial cost trends evolve in 2025?”